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A
s a child, Peter Friedl never envi-
sioned becoming a scientist. But 
curiosity and an aptitude for 
careful observation eventually led him 
to medical school and then the labora-
tory, where his work and career are 
continually evolving.
Friedl completed his MD at Bochum 
in Germany, then decided to indulge his 
burgeoning interest in immunology by 
joining the laboratory of Dr. Kurt Zänker 
at the University of Witten in Germany. 
Zänker sent Friedl to collaborate with 
Peter Noble at McGill University in 
Canada. There, Friedl studied T cell 
and cancer cell migration, fell in love 
with live-cell microscopy, and earned 
his PhD (1, 2). Since then, Friedl has 
leveraged the ever-advancing power 
of microscopy techniques to further 
his migration studies (3–6) and gain 
important insights into the different 
mechanisms of cellular locomotion, and 
the development of metastasis.
Friedl’s work is the product of a 
creative impulse that fi nds its expression 
in long, dark hours behind a microscope. 
When he is not in one of his laboratories—
either the Nijmegen Center for Molecular 
Life Sciences, Netherlands or 
the Rudolf Virchow Center 
in Würzburg, Germany—
his creative impulse fi nds 
another form: oil painting. 
We talked with him about his 
career, the parallels between 
art and science, and his 
works in progress.
TRANSGRESSION
I understand that you’re a trained 
physician in addition to having a PhD?
Yes, but I wouldn’t say I planned to have 
things turn out this way from the start. When 
I was seven or eight, I remember writing in 
a school essay that I wanted to be a bank 
manager, like my father. But actually, I 
didn’t have any idea what I wanted to do. In 
fact, I was something of a troublemaker.
After fi nishing high school, I took 
a year off and basically did nothing. That 
was a very important time for me, because 
it helped me pull myself together, to 
fi gure out what I wanted to do. I realized 
that I wanted to deal with people and 
do something meaningful. I did a civil 
service year in the oncology unit in 
Nuremberg, and decided to go to medical 
school there.
So you completed your medical studies 
ﬁ rst. What made you decide to pursue a 
PhD afterwards?
While I was in medical school, I would 
become very caught up in questions 
that went beyond what we had to mem-
orize for our classes. My imagination 
was always getting in the way of mem-
orization—I kept coming up with all 
these theories about how things might 
work, and ways in which I could test 
my theories. I fell in love with immu-
nology in my third year of medical 
school, and did an immuno-biological 
MD thesis in Bochum. So I thought that 
I should give research a try, and I de-
cided to join the University of Witten, 
which is a small private university in 
Germany, and I worked 
with Dr. Zänker there.
TRANSFORMATION
With Dr. Zänker, you 
started researching cell 
migration—what ﬁ rst 
interested you in that topic?
My father had just died of 
cancer, and immunology 
was my fi rst love, so I 
wanted to bridge the two subjects some-
how. Studying how T cells attack a tumor 
fell perfectly into my personal motiva-
tion and interest. Zänker sent me over to 
McGill to learn cell tracking in the lab-
oratory of Peter Noble, a physiologist, 
and I joined a sort of ad-hoc graduate 
program there; I was Noble’s last gradu-
ate student. We studied T cells moving 
in collagen because you can’t accurately 
observe T cell locomotion in 2D. They 
are suspension cells and they fl oat 
around, so standard 2D cultures don’t 
replicate in vivo conditions very well. I 
remember when I did my very fi rst 
movie of T cells moving in a 3D colla-
gen gel. It was a black and white, poor 
quality movie, but the moment I saw it, 
I knew this was exactly the right thing 
for me.
Is there a particular technology that 
you consider to have been 
transformative for your work?
The fi rst transformation happened when I 
touched a confocal for the fi rst time. With 
bright fi eld microscopy, you see the col-
lagen matrix as a grayish, noisy back-
ground. It looks like jam. With a confocal, 
we saw the refl ection pattern of the col-
lagen fi bers for the fi rst time. This was 
totally revealing! We saw that T cells 
moved like little monkeys in this jungle of 
collagen. They never change the matrix 
structure, they just squeeze themselves 
through the gaps between fi bers. Many 
cancer cells, on the other hand, remodel 
the matrix as they move, leaving behind 
hollow tube-like tracks.
Friedl uses confocal and intravital microscopy to investigate the movement 
of T cells and cancer cells.
Peter Friedl: Painting a picture of cancer immunology
“We saw that 
T cells moved 
like little 
monkeys in 
this jungle of 
collagen.”
Peter Friedl
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As a graduate student at McGill, I’d 
accidentally made a movie of a primary 
tumor that gave out groups of cells that 
moved together, and went through the 
collagen while maintaining their cell–cell 
junctions. Of course this was diffi cult to 
publish, because we couldn’t demonstrate 
the in vivo relevance of this collective 
movement. The dogma in the fi eld was that 
cancer cells need to detach and individualize; 
they still are mostly thought to go as single 
cells through the tissue to metastasize. But, 
we recently published a paper where we 
described how invasive tumor cells remodel 
the extracellular matrix. They leave the main 
tumor mass and degrade the tissue matrix but 
they retain their cell–cell junctions and form 
a long protrusion. This collective migration 
creates these root-like structures: very deep, 
long, multicellular fi ngers. When our multi-
photon imaging platform was fi nally set up, 
it let us image deep in actual tissues and 
observe tumors in vivo, and we observed 
the same phenomenon in vivo. It’s quite 
striking—almost beautiful—to look at.
Beautiful, but a kind of a terrible beauty.
What we are now starting to appreciate is 
that in many cases, cancer invasion—and 
probably also metastatic seeding—is a kind 
of wrongly tuned morphogenesis that hap-
pens in the wrong cell at the wrong time and 
place. It doesn’t have a stop button, so it 
goes on and on. People have called it a non-
healing wound, but you could also call it ill-
fated morphogenesis. Neural tube closure, 
branching morphogenesis, and vascular 
sprouting are all collective 
morphogenesis processes 
that are subverted in cancer.
TRANSCENDENCE
Do you still spend a lot of 
time at the microscope?
I think almost all micro-
scopists like to stay in touch 
with the microscope, be-
cause watching things in real-time provides 
different insights from what you get when 
students or coworkers present images to 
you. So, whenever we start a new set of 
experiments, I tend to participate in the 
imaging myself, until we have the proce-
dures ironed out. It helps me get a more 
intuitive understanding of the model we’re 
using and the experiments we’re running. 
I’ve also noticed that not everybody 
sees the same things, so my views are 
sometimes complementary to what my 
students see. I’ve spent so much time at 
the microscope that I sometimes fi nd 
myself dreaming about it.
As a microscopist, you’re probably a 
very visual person.
Yes, you could say that. In fact, when I’m 
not in the laboratory, I like to paint. For me, 
painting is a way of contemplation. I’ve 
never had any formal training, so it’s all 
autodidactic: I work by trial and error, gen-
erating colorful patterns. I tend to go layer 
by layer, painting over what I don’t like. In 
the end, something is suddenly there that 
feels complete. I have one piece I’ve been 
working on that I’ve decided I will never 
fi nish. I keep painting over it; I think at the 
moment I’m on layer 30. Maybe one day 
it’ll have 1,000 layers. But I’ve also started 
documenting the different stages, and play-
ing them back as a movie, which tells a dif-
ferent story altogether from 
what’s showing on the top 
layer right now.
Is your art inspired by 
your work?
You could look at some of it 
and think that’s the case, 
maybe. I don’t think of it as 
being particularly related. 
But in a way, art and science are not so 
dissimilar. I’ve frequently observed that at 
some point a scientifi c fi nding will detach 
from the person who fi rst made it. It tran-
scends. It gets a new life, and different 
interpretations arise from different audi-
ences; people frequently cite papers for 
something that was not even mentioned in 
the text, but that appeared in a fi gure. 
Paintings also do that; they detach from 
the person who made them, and get a life 
of their own for different observers. That 
is part of what makes both science and art 
so exciting.
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An artistic image created by leakage of 
ﬂ uorescent FITC dextran from a dyed tumor.
Various stages of Friedl’s Layers, a work in progress.
“In a way, 
ar t and 
science 
are not so 
dissimilar.”
(View video compilation of Layers at www.jcb.org)
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